The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Open accessAbstract
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now poses a great threat to human health. Currently, antibiotic options for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) are very limited, with polymyxins, tigecycline, fosfomycin, and aminoglycosides as the mainstays of therapy. The need for new and effective anti-CRE therapies is urgent. Here, we describe the current understanding of issues related to CRE and review potential therapeutic strategies for CRE infections, including high-dose tigecycline, high-dose carbapenem, double carbapenem, and combination therapies. We also review the newly available antibiotics which will play important roles in the future treatment of CRE infections: ceftazidime/avibactam, which is active against KPC and OXA-48 producers, and meropenem/vaborbactam, which is active against KPC producers. Although direct evidence for CRE treatment is still lacking and the development of resistance is a concern, these antibiotics provide promising therapeutic options for CRE infections. Finally, we review other potential anti-CRE antibiotics in development: plazomicin, imipenem/relebactam, cefiderocol, and eravacycline. Currently, high-dose and combination strategies should be considered in severe CRE infections to maximize treatment success. In the future, when more treatment options are available, therapy for CRE infections should be individualized and based on molecular phenotypes of resistance, susceptibility profiles, disease severity, and patient characteristics. More high-quality studies are needed to guide effective treatment for infections caused by CRE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
How antibiotics kill bacteria: from targets to networks
Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2333 · Cited by 2,258
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
The drug-resistant bacteria that pose the greatest health threats
Willyard, C. (2017) · Nature · doi:10.1038/nature.2017.21550 · Cited by 1,221
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 655
Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P.-R., Viale, P., Paño-Pardo, J. R., Venditti, M., Tumbarello, M., Daikos, G., Cantón, R., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30228-1 · Cited by 512
Self-citationTumbarello, M., Trecarichi, E. M., De Rosa, F. G., Giannella, M., Giacobbe, D. R., Bassetti, M., Losito, A. R., Bartoletti, M., Del Bono, V., Corcione, S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv086 · Cited by 511
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Shields, R. K., Chen, L., Cheng, S., Chavda, K. D., Press, E. G., Snyder, A., Pandey, R., Doi, Y., Kreiswirth, B. N., Nguyen, M. H., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02097-16 · Cited by 484
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw636 · Cited by 430
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Evaluation of Methods To Identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae
Anderson, K. F., Lonsway, D. R., Rasheed, J. K., Biddle, J., Jensen, B., McDougal, L. K., Carey, R. B., Thompson, A., Stocker, S., Limbago, B., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00015-07 · Cited by 355
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., Venditti, M., Bordi, E., Capozzi, D., Balice, M. P., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12070 · Cited by 346
ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China
Qi, Y., Wei, Z., Ji, S., Du, X., Shen, P., & Yu, Y. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq431 · Cited by 345
Livermore, D. M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., & Woodford, N. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.01.012 · Cited by 341
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., et al. (2016) · Drugs · doi:10.1007/s40265-016-0545-8 · Cited by 317
Marshall, S., Hujer, A. M., Rojas, L. J., Papp-Wallace, K. M., Humphries, R. M., Spellberg, B., Hujer, K. M., Marshall, E. K., Rudin, S. D., Perez, F., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02243-16 · Cited by 293
Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Tamma, P. D., & Simner, P. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-18 · Cited by 293
Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014) · Critical Care · doi:10.1186/cc13858 · Cited by 245
Daikos, G. L., & Markogiannakis, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03553.x · Cited by 238
Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01288-13 · Cited by 235
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 235
The β‐Lactams Strike Back: Ceftazidime‐Avibactam
Zasowski, E. J., Rybak, J. M., & Rybak, M. J. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1622 · Cited by 218
Endimiani, A., Hujer, A. M., Perez, F., Bethel, C. R., Hujer, K. M., Kroeger, J., Oethinger, M., Paterson, D. L., Adams, M. D., Jacobs, M. R., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn547 · Cited by 216
Martin, A., Fahrbach, K., Zhao, Q., & Lodise, T. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy150 · Cited by 215
Daikos, G. L., Petrikkos, P., Psichogiou, M., Kosmidis, C., Vryonis, E., Skoutelis, A., Georgousi, K., Tzouvelekis, L. S., Tassios, P. T., Bamia, C., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00782-08 · Cited by 210
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Bulik, C. C., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01420-10 · Cited by 200
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-16 · Cited by 182
Castanheira, M., Huband, M. D., Mendes, R. E., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00567-17 · Cited by 170
Nelson, K., Hemarajata, P., Sun, D., Rubio-Aparicio, D., Tsivkovski, R., Yang, S., Sebra, R., Kasarskis, A., Nguyen, H., Hanson, B. M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00989-17 · Cited by 170
Zusman, O., Altunin, S., Koppel, F., Dishon Benattar, Y., Gedik, H., & Paul, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw377 · Cited by 169
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Blizzard, T. A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., Imbriglio, J., Young, K., Park, Y.-W., Ogawa, A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.101 · Cited by 168
Therapeutic Options for Infections with Enterobacteriaceae Producing Carbapenem-Hydrolyzing Enzymes
Falagas, M. E., Karageorgopoulos, D. E., & Nordmann, P. (2011) · Future Microbiology · doi:10.2217/fmb.11.49 · Cited by 167
Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.-C., Brown, M. L., Du, J., Pedley, A., Kartsonis, N. A., & Paschke, A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx139 · Cited by 166
de Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03042-15 · Cited by 162
Trecarichi, E. M., Pagano, L., Martino, B., Candoni, A., Blasi, R. D., Nadali, G., Fianchi, L., Delia, M., Sica, S., Perriello, V. M., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24489 · Cited by 158
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
Wong, D. W., & van Duin, D. (2017) · Drugs · doi:10.1007/s40265-017-0725-1 · Cited by 158
Castón, J. J., Lacort-Peralta, I., Martín‐Dávila, P., Loeches, B., Tabares, S., Temkin, L., Torre‐Cisneros, J., & Paño‐Pardo, J. R. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.03.021 · Cited by 154
Goodman, K., Simner, P. J., Tamma, P. D., & Milstone, A. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1106940 · Cited by 153
Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00436-16 · Cited by 152
Castanheira, M., Rhomberg, P. R., Flamm, R. K., & Jones, R. N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00711-16 · Cited by 135
Thaden, J. T., Pogue, J. M., & Kaye, K. S. (2016) · Virulence · doi:10.1080/21505594.2016.1207834 · Cited by 134
Therapeutic options for carbapenem-resistant Enterobacteriaceae infections
Trecarichi, E. M., & Tumbarello, M. (2017) · Virulence · doi:10.1080/21505594.2017.1292196 · Cited by 131
Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge
Francisco, C. N.-S., Mora-Rillo, M., Romero‐Gómez, M. P., Moreno-Ramos, F., Rico-Nieto, A., Carrascoso, G. R., Gómez-Gil, R., Arribas, J. R., Mingorance, J., & Paño‐Pardo, J. R. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12091 · Cited by 130
Saisho, Y., Katsube, T., White, S., Fukase, H., & Shimada, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-17 · Cited by 124
Castanheira, M., Mills, J. C., Costello, S. E., Jones, R. N., & Sader, H. S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-15 · Cited by 123
Endimiani, A., Hujer, K. M., Hujer, A. M., Armstrong, E. S., Choudhary, Y., Aggen, J. B., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00556-09 · Cited by 118
Walkty, A. J., Adam, H. J., Baxter, M. R., Denisuik, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 116
Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections
Ni, W., Han, Y., Liu, J., Wei, C., Zhao, J., Cui, J., Wang, R., & Liu, Y.-N. (2016) · Medicine · doi:10.1097/md.0000000000003126 · Cited by 112
Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01989-12 · Cited by 108
Sbrana, F., Malacarne, P., Viaggi, B., Costanzo, S., Léonetti, P., Leonildi, A., Casini, B., Tascini, C., & Menichetti, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis969 · Cited by 100
Petty, L. A., Henig, O., Patel, T. S., Pogue, J. M., & Kaye, K. S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s150447 · Cited by 98
Pfaller, M. A., Huband, M. D., Mendes, R. E., Flamm, R. K., & Castanheira, M. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.02.021 · Cited by 96
Castanheira, M., Davis, A. P., Mendes, R. E., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-18 · Cited by 92
Dautzenberg, M. J. D., Ossewaarde, J. M., de Kraker, M. E. A., van der Zee, A., van Burgh, S., de Greeff, S. C., Bijlmer, H. A., Grundmann, H., Stuart, J. W. C., Fluit, A. C., et al. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.9.20723 · Cited by 89
PASCALE, G. D., Martucci, G., Montini, L. M., Panarello, G., Cutuli, S. L., Carlo, D. D., Gravio, V. D., Stefano, R. D., Capitanio, G., Vallecoccia, M. S., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1769-z · Cited by 81
Machuca, I., Gutiérrez‐Gutiérrez, B., Gracia-Ahufinger, I., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00406-17 · Cited by 78
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
Watkins, R., Papp‐Wallace, K. M., Drawz, S. M., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00392 · Cited by 77
Giannella, M., Trecarichi, E. M., Giacobbe, D. R., Rosa, F. G. D., Bassetti, M., Bartoloni, A., Bartoletti, M., Losito, A. R., Bono, V. D., Corcione, S., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.08.019 · Cited by 75
Castanheira, M., Deshpande, L. M., Woosley, L. N., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky344 · Cited by 75
Poirel, L., Kieffer, N., & Nordmann, P. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv294 · Cited by 70
David, M. Z., Dryden, M., Gottlieb, T., Tattevin, P., & Gould, I. M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.006 · Cited by 69
Sheu, C., Lin, S., Chang, Y.-T., Lee, C.-Y., Chen, Y., & Hsueh, P. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1436966 · Cited by 66
Self-citationDupont, H., Gaillot, O., Goetgheluck, A.-S., Plassart, C., Émond, J.-P., Lecuru, M., Gaillard, N., Derdouri, S., Lemaire, B., de Courtilles, M. G., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01559-15 · Cited by 63
Souli, M., Karaiskos, I., Masgala, A., Galani, L., Barmpouti, E., & Giamarellou, H. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2936-5 · Cited by 59
Bulik, C. C., Christensen, H., Li, P., Sutherland, C. A., Nicolau, D. P., & Kuti, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01190-09 · Cited by 56
Zhang, Y., Lin, X., & Bush, K. (2016) · The Journal of Antibiotics · doi:10.1038/ja.2016.73 · Cited by 56
Bono, V. D., Giacobbe, D. R., Marchese, A. E., Parisini, A., Fucile, C., Coppo, E., Marini, V., Arena, A., Molin, A., Martelli, A., et al. (2016) · Virulence · doi:10.1080/21505594.2016.1213476 · Cited by 55
Ting, S.-W., Lee, C., & Liu, J.-W. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2016.08.022 · Cited by 53
Krapp, F., Grant, J. L., Sutton, S. H., Ozer, E. A., & Barr, V. O. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.01.018 · Cited by 51
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00169-18 · Cited by 46
Oliva, A., Scorzolini, L., Castaldi, D., Gizzi, F., Angelis, M. D., Storto, M., D’Abramo, A., Aloj, F., Mascellino, M. T., Mastroianni, C. M., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.10.002 · Cited by 45
Moreno, B. B., Fernández, I., García, V. P., Romero, I. S., Fernández, B. I., Ortega, M. Á. R., Carmona, S. A., Redondo, M. P., & Anuncibay, P. G. (2013) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.861608 · Cited by 42
Ku, Y.-H., Chen, C.-C., Lee, M.-F., Chuang, Y.-C., Tang, H.-J., & Yu, W. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2016.12.008 · Cited by 42
Ni, W., Cai, X., Wei, C., Di, X., Cui, J., Wang, R., & Liu, Y.-N. (2015) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2014.12.004 · Cited by 40
Tseng, S., Wang, S., Ma, L., Wang, T.-Y., Yang, T.-Y., Siu, L.-K. K., Chuang, Y.-C., Lee, P., Wang, J., Wu, T., et al. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.03.003 · Cited by 39
Plazomicin: an investigational therapy for the treatment of urinary tract infections
Karaiskos, I., Souli, M., & Giamarellou, H. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1095180 · Cited by 37
Tang, H.-J., Lai, C.-C., Chen, C.-C., Zhang, C.-C., Weng, T., Chiu, Y.-H., Toh, H. S., Chiang, S., Yu, W.-L., Ko, W., et al. (2016) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2016.03.003 · Cited by 34
Mashni, O. K., Nazer, L. H., & Lê, J. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018790573 · Cited by 34
Fredborg, M., Søndergaard, T. E., & Wang, M. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.04.015 · Cited by 25
Cited by
Bacterial Antibiotic Resistance: The Most Critical Pathogens
Mancuso, G., Midiri, A., Gerace, E., & Biondo, C. (2021) · Pathogens · doi:10.3390/pathogens10101310 · Cited by 1,332
Sawa, T., Kooguchi, K., & Moriyama, K. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-0429-6 · Cited by 296
Key takeaways from the U.S. CDC’s 2019 antibiotic resistance threats report for frontline providers
Kadri, S. S. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004371 · Cited by 292
Lv, L., Wan, M., Wang, C., Gao, X., Yang, Q., Partridge, S. R., Wang, Y., Zong, Z., Doi, Y., Shen, J., et al. (2020) · mBio · doi:10.1128/mbio.02930-19 · Cited by 288
Hammoudi Halat, D., & Ayoub Moubareck, C. (2020) · Antibiotics · doi:10.3390/antibiotics9040186 · Cited by 287
Metadata
- Authors
- Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-30
- Volume
- 10
- Pages
- 80-80
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2913156301
- Cited by
- 520
- References
- 92
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.